Centers for Disease Control and Prevention Model Performance Evaluation Program Human Immunodeficiency Virus Type 1 (HIV-1)Antibody Testing

Figures Used for the Analysis of the January 2001 Performance Evaluation Testing Results Reported by Participant Laboratories



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Public Health Practice Program Office Division of Laboratory Systems Atlanta, Georgia 30341-3724



Use of trade names is for identification only and does not constitute endorsement by the U.S. Department of Health and Human Services.

Report of the January 2001 Human Immunodeficiency Virus Type I (HIV-1) Antibody Performance Evaluation Sample Testing Results Provided by Participant Laboratories in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).

The production of this report was coordinated in CDC by:

Public Health Practice Program Office	Edward L. Baker, M.D., M.P.H., Director
Division of Laboratory Systems	Robert Martin, Dr. P.H., Director
	Thomas L. Hearn, Ph.D., Deputy Director
Laboratory Practice Assessment Branch	Barbara A. Slade, M.D., Chief

The material in this report was developed and prepared by:

Model Performance Evaluation Program (MPEP)	Barbara A. Slade, M.D., Chief
MPEP HIV Performance Evaluation	Marianne K. Simon, M.P.H.
	HIV-1 Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8125 or (770) 488-8137.

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program Human Immunodeficiency Virus Type 1 (HIV-1) Antibody Testing January 2001 Participant Laboratory Shipment

Table 1

Panel Letter	Vial Label	CDC Donor Number	CDC Test Result ¹	Donor HIV Status	Laboratory Interpretation ² EIA
					INIT. ³ FINAL ⁴ WB IIF
А	A1	1	Positive	Infected	
	A2	5 2	Positive Positive	Infected	
	A3,A5			Infected	
	A4,A6	3	Negative	Uninfected	
В	B1,B3	3	Negative	Uninfected	
	B2	1	Positive	Infected	
	B4,B6	2	Positive	Infected	
	B5	5	Positive	Infected	
С	C1,C3	3	Negative	Uninfected	
	C2	5	Positive	Infected	
	C4	1	Positive	Infected	
	C5,C6	2	Positive	Infected	
D	D1	5	Positive	Infected	
	D2,D3	2	Positive	Infected	
	D2,D5 D4,D6	3	Negative	Uninfected	
	D4,00 D5	1	Positive	Infected	
	05	I	FUSITIVE	nnecleu	

¹ The CDC result was obtained after composite testing with all HIV-1 and HIV-1/HIV-2 EIA and HIV-1 WB kits licensed by the Food and Drug Administration (FDA). The CDC WB interpretation is consistent with the manufacturer's criteria for interpretation of WB results.

- ² Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory result with CDC result.
- ³ Initial EIA interpretation
- ⁴ Final EIA interpretation

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program for Human Immunodeficiency Virus Type I (HIV-1) Antibody Testing

Table 2.CDC Western Blot (WB) Testing Results for the
January 2001 Participant Laboratory Panel Samples

Panel Letter	Vial Label	CDC Donor Number	CDC Western Blot Test Results Specific WB Bands Detected ¹	WB Test Kit Manufacturer	CDC Interpretation ²
Α	A1	1	24,55,160	BioRad	Positive
			24,160	Cambridge Biotech*	Positive
			24,51,55,65,120,160	Epitope/Organon	Positive
			24,40,55,120.160	Genetic Systems/Sanofi	Positive
	A2	5	18,24,32,41,51,55,65,120,160	BioRad	Positive
			17,24,31,41,51,55,66,120,160	Cambridge Biotech	Positive
			18,24,31,41,51,55,65,120,160	Epitope/Organon	Positive
			18,24,31,40,41,51,55,65,120,160	Genetic Systems/Sanofi	Positive
	A3, A5	2	24,32,41,51,55,65,120,160	BioRad	Positive
			17,24,31,41,51,66,120,160	Cambridge Biotech	Positive
			24,31,41,51,55,65,120,160	Epitope/Organon	Positive
			24,31,40,41,51,55,65,120,160	Genetic Systems/Sanofi	Positive
	A4, A6	3	No Bands	All Manufacturers	Negative
в	B1, B3	3	No Bands	All Manufacturers	Negative
	B2	1	24,55,160	BioRad	Positive
			24,160	Cambridge Biotech	Positive
			24,51,55,65,120,160	Epitope/Organon	Positive
B4, B6			24,40,55,120.160	Genetic Systems/Sanofi	Positive
	B4, B6	2	24,32,41,51,55,65,120,160	BioRad	Positive
			17,24,31,41,51,66,120,160	Cambridge Biotech	Positive
			24,31,41,51,55,65,120,160	Epitope/Organon	Positive
			24,31,40,41,51,55,65,120,160	Genetic Systems/Sanofi	Positive
	B5	5	18,24,32,41,51,55,65,120,160	BioRad	Positive
			17,24,31,41,51,55,66,120,160	Cambridge Biotech	Positive
			18,24,31,41,51,55,65,120,160	Epitope/Organon	Positive
			18,24,31,40,41,51,55,65,120,160	Genetic Systems/Sanofi	Positive

Table 2, continued b b b b b b b b b b b

¹ Western blot (WB) result based on band intensity of \geq 1+ staining.

² The CDC interpretation is consistent with the manufacturer's criteria for interpretation of WB results.

* Cambridge Biotech/Calypte Biomedical

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program for Human Immunodeficiency Virus Type I (HIV-1) Antibody Testing

<u>Table 2.</u> CDC Western Blot (WB) Testing Results for the (Cont'd) January 2001 Participant Laboratory Panel Samples

Panel Letter	Vial Label	CDC Donor Number	CDC Western Blot Test Results Specific WB Bands Detected ¹	WB Test Kit Manufacturer	CDC Interpretation ²
С	C1, C3	3	No Bands	All Manufacturers	Negative
	C2	5	18,24,32,41,51,55,65,120,160 17,24,31,41,51,55,66,120,160 18,24,31,41,51,55,65,120,160 18,24,31,40,41,51,55,65,120,160	BioRad Cambridge Biotech* Epitope/Organon Genetic Systems/Sanofi	Positive Positive Positive Positive
	C4	1	24,55,160 24,160 24,51,55,65,120,160 24,40,55,120.160	BioRad Cambridge Biotech Epitope/Organon Genetic Systems/Sanofi	Positive Positive Positive Positive
	C5, C6	2	24,32,41,51,55,65,120,160 17,24,31,41,51,66,120,160 24,31,41,51,55,65,120,160 24,31,40,41,51,55,65,120,160	BioRad Cambridge Biotech Epitope/Organon Genetic Systems/Sanofi	Positive Positive Positive Positive
D	D1	5	18,24,32,41,51,55,65,120,160 17,24,31,41,51,55,66,120,160 18,24,31,41,51,55,65,120,160 18,24,31,40,41,51,55,65,120,160	BioRad Cambridge Biotech Epitope/Organon Genetic Systems/Sanofi	Positive Positive Positive Positive
	D2, D3	2	24,32,41,51,55,65,120,160 17,24,31,41,51,66,120,160 24,31,41,51,55,65,120,160 24,31,40,41,51,55,65,120,160	BioRad Cambridge Biotech Epitope/Organon Genetic Systems/Sanofi	Positive Positive Positive Positive
	D4, D6	3	No Bands	All Manufacturers	Negative
	D5	1	24,55,160 24,160 24,51,55,65,120,160 24,40,55,120.160	BioRad Cambridge Biotech Epitope/Organon Genetic Systems/Sanofi	Positive Positive Positive Positive

¹ Western blot (WB) result based on band intensity of \geq 1+ staining.


² The CDC interpretation is consistent with the manufacturer's criteria for interpretation of WB results.

* Cambridge Biotech/Calypte Biomedical

SUPPLEMENTAL INFORMATION FOR COMPREHENDING THE NUMBERS USED TO LABEL FIGURES IN THIS REPORT

The "N=" that appears on each graph represents the number of laboratories that reported results. For some graphs, laboratories reported results using more than one test; therefore, the number of results may exceed the actual number of laboratories providing reports. In figures 1-7 and 10, the vertical axis is labeled either as frequency or percentage of results; in figures 8 and 9, this axis is labeled as percentage of reports. However, in all figures, the number appearing directly above or within each bar represents a frequency of results only.

Figure 1. Frequency of HIV-1 antibody test result interpretations, by sample type (reactivity), for enzyme immunoassay (EIA), Western blot (WB), and indirect immunofluorescence (IIF), reported by participant laboratories for the January 23, 2001 shipment



CDC Model Performance Evaluation Program HIV-1 Antibody Testing

Figure 2. Percentage of HIV-1 participant laboratories, by laboratory type, that reported EIA, WB, and IIF results to the CDC for the January 23, 2001 shipment






Figure 3. Combination of HIV-1 antibody tests reported by participant laboratories for the January 23, 2001 shipment





Test Combinations

Figure 4. Types of HIV-1 antibody test kits used for enzyme immunoassay, Western blot, and indirect immunofluorescence, as reported by participant laboratories to the CDC for the January 23, 2001 shipment










Test Result Interpretations

Non-Reactive Reactive

Figure 6. Western blot HIV-1 antibody test results, by kit manufacturer, reported by participant laboratories for the January 23, 2001 shipment








Figure 7. Indirect immunofluorescence HIV-1 antibody test results, by kit manufacturer, reported by participant laboratories for the January 23, 2001 shipment





Test Result Interpretations




Figure 8. Western blot HIV-1 antibody band patterns reported to CDC by participant laboratories for the January 23, 2001 shipment





Figure 9. Fluorescence intensity patterns, of HIV-1-infected cells, for IIF results reported to CDC by participant laboratories for the January 23, 2001 shipment





Test Result Interpretations